References
- National Clinical Guideline Centre (UK)Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary CareLondonNational Institute for Health and Care Excellence (UK)201410NICE Clinical Guidelines, No. 186 Available from: https://www.ncbi.nlm.nih.gov/books/NBK248064/Accessed 20 February, 2018
- KobeltGThompsonABergJNew insights into the burden and costs of multiple sclerosis in EuropeMult Scler20172381123113628273775
- HauserSLChanJROksenbergJRMultiple sclerosis: prospects and promiseAnn Neurol201374331732723955638
- NylanderAHaflerDAMultiple sclerosisJ Clin Invest201212241180118822466660
- BayasAMäurerMTeriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherencePatient Prefer Adherence2015926527425709412
- MSFIAtlas of MS 2013: mapping multiple sclerosis around the world (pdf)Multiple Sclerosis International Federation2013 Available from: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdfAccessed 20 February 2018
- GoldLSSuhKSchepmanPBDamalKHansenRNHealthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel®Adv Ther20163381279129227312977
- FernándezOAgüeraEAgüeraJAdherence to interferon β-1b treatment in patients with multiple sclerosis in SpainPLoS One201275e3560022615737
- Sicras-MainarARuíz-BeatoENavarro-ArtiedaRMaurinoJImpact on healthcare resource utilization of multiple sclerosis in SpainBMC Health Serv Res201717185429284493
- HaaseRKullmannJSZiemssenTTherapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS surveyTher Adv Neurol Disord20169425026327366231
- OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
- SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
- EvansCMarrieRAZhuFAdherence and persistence to drug therapies for multiple sclerosis: a population-based studyMult Scler Relat Disord20168788527456879
- MckayKATremlettHPattenSBDeterminants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective studyMult Scler201723458859627357507
- MoriskyDEGreenLWLevineDMConcurrent and predictive validity of a self-reported measure of medication adherenceMed Care198624167743945130
- García PérezAMLeiva FernándezFMartos CrespoFGarcía RuízAJPrados TorresDSánchez de la Cuesta y AlarcónF¿Cómo diagnosticar el cumplimiento terapéutico en atención primaria? [How to diagnose therapeutic compliance in primary care?]Medicina de Familia200011319
- CâmaraNAACGondimAPSFactors associated with adherence to immunomodulator treatment in people with multiple sclerosisBraz J Pharm Sci2017531e16132
- MunsellMFreanMMenzinJPhillipsALAn evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drugPatient Prefer Adherence201711556228115831
- HuynhTKOstergaardAEgsmoseCMadsenORPreferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritisPatient Prefer Adherence20148939924470758
- Society NMSLos Medicamentos Modificadores de la Esclerosis Múltiple1–362016 Available from: https://www.nationalms-society.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-Los-Medicamentos-Modificadores-de-la-Esclerosis-Multiple.pdfNational Multiple Sclerosis SocietyAccessed 11 January, 2019
- DevonshireVLapierreYMacDonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2011181697720561039
- PozoMAlonsoMMartosMSalvadorFMartínezCAdherence to treatment by public administration workers: factors related to health and well-beingMedicina y Seguridad del Trabajo2009552156371
- HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
- HigueraLCarlinCSAndersonSAdherence to disease-modifying therapies for multiple sclerosisJ Manag Care Spec Pharm201622121394140127882830
- OdlAaTAdherencia al tratamiento en la Comunidad de Madrid Available from: link:https://www.sefac.org/sites/default/files/sefac2010/private/documentos_sefac/documentos/farmaindustria-plan-de-adherencia.pdfAccessed 17 November, 2017
- RemingtonGRodriguezYLoganDWilliamsonCTreadawayKFacilitating medication adherence in patients with multiple sclerosisInt J MS Care2013151364524453761
- HollandNWieselPCavalloPAdherence to disease-modifying therapy in multiple sclerosis: part IRehabil Nurs200126517217612035685
- ConthePMárquez ContrerasEAliaga PérezAAdherencia terapéutica en la enfermedad crónica: estado de la situación y perspectiva de futuro [Therapeutic adherence in chronic disease: status of the situation and perspective for the future]Revista Clínica Española2014214633634424816042
- SimpsonSHEurichDTMajumdarSRA meta-analysis of the association between adherence to drug therapy and mortalityBMJ200633375571516790458
- ChrystynHSmallMMilliganGHigginsVGilEGEstruchJImpact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPDRespir Med2014108235836524209768
- WongWSChowYFChenPPWongSFieldingRA longitudinal analysis on pain treatment satisfaction among Chinese patients with chronic pain: predictors and association with medical adherence, disability, and quality of lifeQual Life Res20152492087209725749925
- ZimmerABläuerCCoslovskyMKapposLDerfussTOptimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfactionMult Scler Relat Disord20154544445026346793
- FernándezODuranEAyusoTTreatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)PLoS One20171210e018576629049356
- JohnsonKMZhouHLinFKoJJHerreraVReal-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 yearJ Manag Care Spec Pharm201723884485228737986
- GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762